MARKET

INSM

INSM

Insmed Inc
NASDAQ
26.52
+1.50
+6.00%
After Hours: 26.60 +0.08 +0.30% 16:04 12/01 EST
OPEN
24.96
PREV CLOSE
25.02
HIGH
26.53
LOW
24.51
VOLUME
1.71M
TURNOVER
0
52 WEEK HIGH
27.59
52 WEEK LOW
16.04
MARKET CAP
3.79B
P/E (TTM)
-5.0329
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at INSM last week (1120-1124)?
Weekly Report · 6d ago
JP Morgan bullish on six Big Biotechs, rates nine others neutral or lower
Jp morgan bullish on six big biotechs, rates nine others neutral or lower. Insmed, denali, immunocore, crinetics, mirum and biocryst among those rated overweight. Investment bank was less keen on cervel therapeutics, alkermes and esperion.
Seeking Alpha · 11/25 21:32
Where Insmed Stands With Analysts
7 analysts have published their opinion on insmed (nasdaq:insm) over the past 3 months. These analysts have an average price target of $45.57 for insmed stock. These 7 analysts are typically employed by large wall street banks and typically rate stocks once a quarter.
Benzinga · 11/20 17:00
JP Morgan Reinstates Overweight on Insmed, Announces $36 Price Target
Benzinga · 11/20 12:56
Weekly Report: what happened at INSM last week (1113-1117)?
Weekly Report · 11/20 09:15
Insmed Inc: [Amend]Statement of acquisition of beneficial ownership by individuals
Press release · 11/13 18:19
Weekly Report: what happened at INSM last week (1106-1110)?
Weekly Report · 11/13 09:15
Weekly Report: what happened at INSM last week (1030-1103)?
Weekly Report · 11/06 09:14
More
About INSM
Insmed Incorporated is a biopharmaceutical company. It is engaged in providing ARIKAYCE (amikacin liposome inhalation suspension) product, which is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its clinical-stage pipeline includes brensocatib and treprostinil palmitil inhalation powder (TPIP). Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1, which is developed for the treatment of patients with bronchiectasis, cystic fibrosis (CF) and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRS) and hidradenitis suppurativa (HS). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil which offers a differentiated product profile for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Webull offers Insmed Incorporated stock information, including NASDAQ: INSM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INSM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INSM stock methods without spending real money on the virtual paper trading platform.